PMEDAP

Category	Cytomegalovirus (CMV)
CAS	113852-41-8
Description	PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication with anti-murine cytomegalovirus (MCMV) activity, and is a very potent inhibitor of moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. It has been studied for potential treatment of feline herpesvirus 1 (FHV-1).

Quotation Now

Synonyms	9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine; N-(2-Phosphonomethoxyethyl)-2,6-diaminopurine; PME-DAP; ((2-(2,6-Diamino-9H-purin-9-yl)ethoxy)methyl)phosphonic acid; Phosphonic acid, ((2-(2,6-diamino-9H-purin-9-yl)ethoxy)methyl)-; GS 0573
IUPAC Name	2-(2,6-diaminopurin-9-yl)ethoxymethylphosphonic acid
Molecular Weight	288.20
Molecular Formula	C8H13N6O4P
Canonical SMILES	C1=NC2=C(N=C(N=C2N1CCOCP(=O)(O)O)N)N
InChI	InChI=1S/C8H13N6O4P/c9-6-5-7(13-8(10)12-6)14(3-11-5)1-2-18-4-19(15,16)17/h3H,1-2,4H2,(H2,15,16,17)(H4,9,10,12,13)
InChIKey	XHXFQGAZAVKMFF-UHFFFAOYSA-N
Boiling Point	748.7±70.0°C at 760 mmHg
Flash Point	406.6°C
Purity	≥98%
Density	2.0±0.1 g/cm3
Solubility	In vitro: 10 mM in DMSO
Appearance	Solid Powder
Storage	Store at 2-8°C, protect from light
Complexity	354
Exact Mass	288.07358991
Index Of Refraction	1.826
In Vivo	PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV.
PSA	172.94000
Target	HIV; CMV
Vapor Pressure	1.51E-23mmHg at 25°C
XLogP3-AA	-2.6